Both PLX-NP and P-aPD-1 are harbored in the hydrogel to form a local delivery reservoir, in which PLX is gradually released to deplete TAMs to recruit T cells toward tumor parenchyma, favoring the subsequent efficacy of the anti-PD-1 immunotherapy. The gene discussed is PDCD1; the disease is neoplasm.